These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Winner JG; Carhart JM; Altar CA; Goldfarb S; Allen JD; Lavezzari G; Parsons KK; Marshak AG; Garavaglia S; Dechairo BM Curr Med Res Opin; 2015; 31(9):1633-43. PubMed ID: 26086890 [TBL] [Abstract][Full Text] [Related]
3. Economic Utility: Combinatorial Pharmacogenomics and Medication Cost Savings for Mental Health Care in a Primary Care Setting. Brown LC; Lorenz RA; Li J; Dechairo BM Clin Ther; 2017 Mar; 39(3):592-602.e1. PubMed ID: 28238356 [TBL] [Abstract][Full Text] [Related]
4. Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications. Tanner JA; Brown LC; Yu K; Li J; Dechairo BM Clinicoecon Outcomes Res; 2019; 11():779-787. PubMed ID: 31849503 [TBL] [Abstract][Full Text] [Related]
5. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders. Benitez J; Cool CL; Scotti DJ Per Med; 2018 Nov; 15(6):481-494. PubMed ID: 30256179 [TBL] [Abstract][Full Text] [Related]
6. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Rothschild AJ; Parikh SV; Hain D; Law R; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Shelton RC; Macaluso M; Brown K; Lewis D; Gutin A; Jablonski MR; Greden JF Psychiatry Res; 2021 Feb; 296():113649. PubMed ID: 33360967 [TBL] [Abstract][Full Text] [Related]
7. Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population. Lunenburg CATC; Hauser AS; Ishtiak-Ahmed K; Gasse C Clin Transl Sci; 2020 Jul; 13(4):798-806. PubMed ID: 32166845 [TBL] [Abstract][Full Text] [Related]
8. Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders: A Randomized Controlled Trial. Olson MC; Maciel A; Gariepy JF; Cullors A; Saldivar JS; Taylor D; Centeno J; Garces JA; Vaishnavi S Prim Care Companion CNS Disord; 2017 Mar; 19(2):. PubMed ID: 28314093 [TBL] [Abstract][Full Text] [Related]
9. Combinatorial pharmacogenomics and improved patient outcomes in depression: Treatment by primary care physicians or psychiatrists. Tanner JA; Davies PE; Voudouris NC; Shahmirian A; Herbert D; Braganza N; Gugila A; Dechairo BM; Kennedy JL J Psychiatr Res; 2018 Sep; 104():157-162. PubMed ID: 30081389 [TBL] [Abstract][Full Text] [Related]
10. Drug Prescribing and Outcomes After Pharmacogenomic Testing in a Developmental and Behavioral Health Pediatric Clinic. Patel JN; Mueller MK; Guffey WJ; Stegman J J Dev Behav Pediatr; 2020 Jan; 41(1):65-70. PubMed ID: 31688658 [TBL] [Abstract][Full Text] [Related]
11. National trends in psychotropic medication polypharmacy in office-based psychiatry. Mojtabai R; Olfson M Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220 [TBL] [Abstract][Full Text] [Related]
12. Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. Ilyas S; Moncrieff J Br J Psychiatry; 2012 May; 200(5):393-8. PubMed ID: 22442100 [TBL] [Abstract][Full Text] [Related]
13. Comparisons of the costs of psychotropic medications: an update. Jurman RJ; Davis JM Psychiatr Med; 1991; 9(2):349-59. PubMed ID: 1677482 [TBL] [Abstract][Full Text] [Related]
14. Impact of Pharmacogenomics on Pediatric Psychotropic Medication Prescribing in an Ambulatory Care Setting. Tonti E; Lee YM; Gruenke N; Ferren J; Stutzman DL J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):52-60. PubMed ID: 38377527 [No Abstract] [Full Text] [Related]
15. Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients. Maghari S; Gallo T; Rivas S; German A; Nguyen Le MQ; Abbaszadegan H; Zubriski MA; Heise CW; Landas ND Pharmacogenomics; 2023 Jun; 24(9):501-508. PubMed ID: 37435738 [No Abstract] [Full Text] [Related]
19. First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients. West JC; Wilk JE; Rae DS; Muszynski IL; Rubio-Stipec M; Alter CL; Sanders KE; Crystal S; Regier DA J Clin Psychiatry; 2010 Apr; 71(4):400-10. PubMed ID: 19925748 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective. Tanner JA; Davies PE; Overall CC; Grima D; Nam J; Dechairo BM Pharmacogenomics; 2020 Jun; 21(8):521-531. PubMed ID: 32301648 [No Abstract] [Full Text] [Related] [Next] [New Search]